The Clinical Trial of Difference Between Formaderm Lidocaine and Formaderm Dermal Filler Injection

Exclusion Criteria

• •Women subjects who are pregnant, breastfeeding, planning to become pregnant, and not willing to take contraception during the trial period.
• •Subjects with history of allergies to hyaluronic acid.
• •Subjects with history of allergies to lidocaine or amide-type local anesthetics.
• •Those who are suffering from immunity related disorder.
• •Those who are suffering from a mental disease.
• •Those who are suffering from alcohol use disorder.
• •Those who have severe heart, kidney, liver or respiratory system disorder.
• •Those who have localized infection, severe skin disease, inflammation, tumor or other related disease in the nasolabial fold area.
• •Those with a scar-prone constitution, prone to scar formation, hypertrophic scars or keloids.
• •Those with coagulation disorder
• •Patients undergoing anticoagulant treatment or taking non-steroidal anti-inflammatory drug(NSAID) within the past 1 week before screening.
• •Those with permanent implants in the nasolabial fold area.
• •Those who have undergone chemical peels treatment within the last 4 weeks before screening.
• •Those who have undergone cosmetic treatment or surgery prior in the nasolabial fold area within the last 24 weeks before screening, such as botox injections, laser treatment of dermal lesions, or plastic surgery.
• •Those who have undergone nasolabial fold augmentation treatment within the past 52 weeks before screening, such as autologous fat grafting, hyaluronic acid implants or collagen implants.
• •Those who have joined other clinical trials within the past 12 weeks before screening (except for the clinical trials of questionnaire or sample collection)
• •Those who are unable to comply with re-visit schedule.
• •Those whose medication and medical conditions are deemed unfit for inclusion in the research based on the judgment of the researcher.